Taysha Gene Therapies (TSHA) EBITDA (2020 - 2026)

Taysha Gene Therapies has disclosed EBITDA across 7 years of filings, most recently posting -$43.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$43.5 million, down 103.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$132.6 million (down 49.7% YoY), and the FY2025 annual result was -$110.5 million, down 20.82% from the prior year.
• EBITDA came in at -$43.5 million for Q1 2026 at Taysha Gene Therapies, down from -$28.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$16.2 million in Q4 2023 to a low of -$54.0 million in Q4 2022.
• The 5-year median for EBITDA is -$25.5 million (2022), against an average of -$28.3 million.
• Across the five-year window, EBITDA soared 69.9% in 2023 and tumbled 103.01% in 2026, its largest moves.
• Taysha Gene Therapies' EBITDA stood at -$54.0 million in 2022, then soared by 69.9% to -$16.2 million in 2023, then slipped by 22.69% to -$19.9 million in 2024, then tumbled by 41.98% to -$28.3 million in 2025, then slumped by 53.66% to -$43.5 million in 2026.
• The last three EBITDA figures came in at -$43.5 million (Q1 2026), -$28.3 million (Q4 2025), and -$34.0 million (Q3 2025), per Business Quant data.